CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 108 enrolled
Drug / intervention
Ripretinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04633122
NCT04633122Phase 2Completed
CompareCT.gov

A Phase 2, Randomized, Multicenter, Open-label Study of DCC-2618 (Ripretinib, ZL-2307 ) vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib

Zai Lab (Shanghai) Co., Ltd.·interventional·Posted Nov 18, 2020·Updated Apr 3, 2026

In Brief

A Phase 2 clinical trial evaluating Ripretinib and Sunitinib for Gastrointestinal Stromal Tumor(GIST). Completed, enrolled 108 participants across 18 sites.

Detailed Summary

the primary objective of this study is to assess the efficacy (progression-free survival,PFS) of DCC-2618 (ripretinib, ZL-2307) and sunitinib in patients with advanced gastrointestinal stromal tumors after treatment with imatinib. This study will enroll approximately 98 subjects in around 18 sites in China mainland, and all subjects will be receiving DCC-2618 or Sunitinib in equal chance as treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastrointestinal Stromal Tumor(GIST)
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedNov 18, 2020
Enrollment StartNov 25, 2020
Primary CompletionJul 20, 2022
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 5.6 years ago

Interventions

Ripretinibdrug

Oral kinase inhibitor

Sunitinibdrug

second-line therapy in GIST patients who have progressed after imatinib treatment or are intolerant to imatinib